
HGH (Somatropin)
Growth hormone itself. It bypasses the pituitary entirely, which explains both its power and its risk.
- Evidence
- AApproved what's this?
Grade A for deficiency. Enhancement in non-deficient adults is unsupported, and the risk outweighs the benefit. - Also known as
- Somatropin · rhGH · 191AA GH · Genotropin, Omnitrope, Humatrope, Norditropin and others
- Class
- Recombinant human growth hormone. Approved prescription hormone.
What it is
Every other GH-axis compound in this guide nudges the pituitary to release more of its own growth hormone. HGH skips that step and puts the hormone straight into the blood. That makes it far more powerful than any secretagogue, and it can push levels well past anything the body would produce naturally. That’s where both the benefits and the dangers come from.
How it works
With no pituitary brake, the body’s own GH production is suppressed by feedback for as long as you use it.
What the research shows
It’s one of the most studied hormones in medicine. In deficiency, replacement reduces fat mass, increases lean mass, raises bone density, improves lipids and quality of life, and restores growth in children1,3. Long-term surveillance shows that at proper doses glucose control stays largely stable, though it needs watching2. In non-deficient adults, it produces some body-composition change alongside a consistent rise in side effects, and medical consensus is that the risks outweigh the benefits1.
Evidence at a glance
| Use | Grade | Best evidence | Main gap | Read |
|---|---|---|---|---|
| Adult GH deficiency | AApproved | Less fat, more lean, better bone and lipids1,3 | For the deficient | Proven |
| Childhood growth disorders | AApproved | Restores growth1 | Specialist care | Proven |
| Body composition, non-deficient | BHuman trials | Real effect, more side effects | Unapproved; banned in sport | Ill-advised |
| Anti-ageing, non-deficient | BHuman trials | Risk outweighs benefit1 | Not supported | Not recommended |
Dosing: what has been reported
| Setting | Figure | Route | Grade |
|---|---|---|---|
| Adult deficiency (approved) | Start ~0.2 mg/day (0.6 IU); 0.1–0.2 mg if over 60; adjust every 1–2 months to mid-normal IGF-1; maintenance often 0.4–0.5 mg/day | Subcutaneous, daily | A |
| Children (approved) | Per kg, e.g. GHD 0.024–0.034 mg/kg/day; Turner ~0.045–0.05 mg/kg/day | Subcutaneous, daily | A |
| HIV wasting (approved) | ~0.1 mg/kg/day, max 6 mg/day | Subcutaneous | A |
| Off-label community | 1–8 IU/day and higher; risk rises steeply above ~4 IU/day | Subcutaneous | D |
Preparing & storing
GH is a large, fragile protein. Reconstitute with the supplied diluent following the product instructions, never shake it, keep it refrigerated and use it within the stated window. These rules are stricter than for small research peptides.
Reported side effects
- Fluid retention and swelling (about a third of patients at higher doses)
- Joint and muscle pain; carpal tunnel syndrome
- Raised blood sugar and insulin resistance
- Headaches, raised blood pressure, gynaecomastia
- Uncommon but serious: pancreatitis, raised intracranial pressure; long-term cancer risk is debated
Interacts with insulin, corticosteroids, and thyroid and sex hormones. Medical monitoring covers IGF-1, glucose, insulin, thyroid, blood pressure and lipids.
Who should avoid it
- Active or past cancer
- Uncontrolled diabetes or significant insulin resistance
- Acute critical illness (specifically contraindicated)
- Pregnancy and breastfeeding; certain eye and intracranial conditions
- Tested athletes: WADA prohibited, detectable
Regulatory status checked Oct 2026
| Body | Status | Detail |
|---|---|---|
| FDA (US) | Approved, restricted | Distributing GH for anything other than an approved indication is a crime under US law. |
| EMA (EU) | Approved | Prescription only. |
| CDSCO (India) | Approved | Somatropin brands, prescription only. |
| WADA | Prohibited | Banned at all times; detectable. |
Real medicine for real deficiency
HGH is powerful and genuinely helpful for people who lack it. For everyone else, the side effects and the legal and sporting consequences outweigh the gains. If GH is the goal, start with testing and a doctor, not a vial.
References
- Somatropin for growth hormone deficiency. StatPearls. NCBI Bookshelf NBK596750.
- Beck-Peccoz P, et al. No increased risk of glucose metabolism disorders in adults with GHD on long-term biosimilar somatropin (Omnitrope). PMC6907272.
- Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult GH deficiency: Endocrine Society guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609.